These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24378707)

  • 1. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.
    Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
    Eur J Med Chem; 2014 Feb; 73():30-7. PubMed ID: 24378707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
    Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
    Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.
    Maina T; Cescato R; Waser B; Tatsi A; Kaloudi A; Krenning EP; de Jong M; Nock BA; Reubi JC
    J Med Chem; 2014 Aug; 57(15):6564-71. PubMed ID: 25007399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.
    Reubi JC; Schär JC; Waser B; Wenger S; Heppeler A; Schmitt JS; Mäcke HR
    Eur J Nucl Med; 2000 Mar; 27(3):273-82. PubMed ID: 10774879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.
    Antunes P; Ginj M; Walter MA; Chen J; Reubi JC; Maecke HR
    Bioconjug Chem; 2007; 18(1):84-92. PubMed ID: 17226960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.
    Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
    EJNMMI Res; 2012 Jun; 2(1):25. PubMed ID: 22682002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [
    Tatsi A; Maina T; Waser B; Krenning EP; de Jong M; Reubi JC; Cordopatis P; Nock BA
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
    Nock BA; Maina T; Krenning EP; de Jong M
    J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.
    Froidevaux S; Heppeler A; Eberle AN; Meier AM; Häusler M; Beglinger C; Béhé M; Powell P; Mäcke HR
    Endocrinology; 2000 Sep; 141(9):3304-12. PubMed ID: 10965902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
    Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
    J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting.
    Heppeler A; André JP; Buschmann I; Wang X; Reubi JC; Hennig M; Kaden TA; Maecke HR
    Chemistry; 2008; 14(10):3026-34. PubMed ID: 18246556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
    Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, and Biological Evaluation of
    Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
    Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
    Eisenwiener KP; Prata MI; Buschmann I; Zhang HW; Santos AC; Wenger S; Reubi JC; Mäcke HR
    Bioconjug Chem; 2002; 13(3):530-41. PubMed ID: 12009943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.
    Ginj M; Schmitt JS; Chen J; Waser B; Reubi JC; de Jong M; Schulz S; Maecke HR
    Chem Biol; 2006 Oct; 13(10):1081-90. PubMed ID: 17052612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model.
    Froidevaux S; Eberle AN; Christe M; Sumanovski L; Heppeler A; Schmitt JS; Eisenwiener K; Beglinger C; Mäcke HR
    Int J Cancer; 2002 Apr; 98(6):930-7. PubMed ID: 11948475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
    Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
    J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
    Antunes P; Ginj M; Zhang H; Waser B; Baum RP; Reubi JC; Maecke H
    Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):982-93. PubMed ID: 17225119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog.
    Reubi JC; Erchegyi J; Cescato R; Waser B; Rivier JE
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1551-8. PubMed ID: 20396884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.